[{"id":"3e8a0f3b-3463-4d31-a604-43157b0a68a9","acronym":"SCOPE","url":"https://clinicaltrials.gov/study/NCT04079166","created_at":"2021-01-18T19:58:29.386Z","updated_at":"2024-07-02T16:35:21.526Z","phase":"Phase 2","brief_title":"SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)","source_id_and_acronym":"NCT04079166 - SCOPE","lead_sponsor":"Scancell Ltd","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • SCIB1"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 08/19/2019","start_date":" 08/19/2019","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2024-01-31"}]